Further clinical development of vidutolimod may also be attractive in earlier stages of melanoma, given that the combination of neoadjuvant vidutolimod plus anti–PD‐1 therapy demonstrated encouraging pathologic response rates in a single‐arm pilot study for patients with resectable stage III melanoma,32 which led to a randomized phase 2 study (ClinicalTrials.gov identifier NCT04708418). The gene discussed is PDCD1; the disease is melanoma.